|
|
|
Insider
Information: |
Cox John |
Relationship: |
|
City: |
Weston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
44,968 |
|
Indirect Shares
|
4,444 |
|
|
Direct
Value |
$9,091,169 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
49,412 |
|
|
Total
Value |
$9,091,169 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
4
|
Stock
price went up :
|
0
|
4
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
Percentage
Gain/Loss : |
0.0%
|
401.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biogen Idec Inc |
BIIB |
EVP Pharmaceutical Ope... |
2016-04-01 |
39,045 |
|
0 |
Premium* |
|
Repligen Corp |
RGEN |
Director |
2020-03-24 |
923 |
2015-05-21 |
0 |
Premium* |
|
Bioverativ Inc. |
BIVV |
Chief Executive Office... |
2018-03-08 |
0 |
2017-02-28 |
0 |
Premium* |
|
Sigilon Therapeutics, Inc. |
SGTX |
|
2023-08-11 |
0 |
2020-12-08 |
4,444 |
Premium* |
|
Dyne Therapeutics, Inc. |
DYN |
|
2024-03-25 |
5,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,339 |
215,680 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(185,094) |
0 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2018-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,486 |
6,313 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,236 |
0 |
- |
|
SGTX |
Sigilon Therapeutics, Inc... |
Director |
|
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
4,444 |
4,444 |
0 |
- |
|
SGTX |
Sigilon Therapeutics, Inc... |
|
|
2023-08-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(341) |
0 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2010-11-01 |
4 |
D |
$62.55 |
$22,518 |
D/D |
(360) |
17,894 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-02-23 |
4 |
D |
$66.76 |
$45,397 |
D/D |
(680) |
15,061 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2010-11-02 |
4 |
AS |
$63.04 |
$48,228 |
D/D |
(765) |
17,129 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2010-11-09 |
4 |
AS |
$62.87 |
$48,597 |
D/D |
(773) |
16,356 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-02-12 |
4 |
D |
$65.83 |
$59,905 |
D/D |
(910) |
15,446 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-05-03 |
4 |
D |
$97.99 |
$74,962 |
D/D |
(765) |
9,588 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-02-24 |
4 |
D |
$67.26 |
$80,847 |
D/D |
(1,202) |
13,859 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2016-02-23 |
4 |
D |
$258.99 |
$98,934 |
D/D |
(382) |
30,516 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2012-05-03 |
4 |
D |
$134.26 |
$102,709 |
D/D |
(765) |
12,178 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-03-31 |
4 |
OE |
$43.50 |
$123,540 |
D/D |
2,840 |
12,658 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-02-17 |
4 |
AS |
$67.08 |
$123,620 |
D/D |
(1,843) |
13,603 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2012-02-23 |
4 |
D |
$116.70 |
$126,620 |
D/D |
(1,085) |
14,291 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-04 |
4 |
OE |
$12.91 |
$129,100 |
D/D |
10,000 |
12,781 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-11-01 |
4 |
OE |
$72.87 |
$158,492 |
D/D |
2,175 |
11,763 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-11 |
4 |
OE |
$9.53 |
$175,171 |
D/D |
18,381 |
199,013 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2012-02-09 |
4 |
D |
$117.78 |
$177,141 |
D/D |
(1,504) |
12,776 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-24 |
4 |
S |
$96.72 |
$179,706 |
D/D |
(1,858) |
923 |
0 |
% |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2012-02-24 |
4 |
D |
$116.39 |
$183,663 |
D/D |
(1,578) |
12,713 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2013-02-08 |
4 |
D |
$164.44 |
$186,311 |
D/D |
(1,133) |
14,532 |
0 |
- |
|
85 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|